ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case (CLPT)
· seekingalpha.com
ClearPoint Neuro's Q2 miss and preclinical delays weigh on 2026, but regulatory clarity boosts 2027-28 upside. Click to see risks, dilution and outlook.
ClearPoint Neuro's ( CLPT ) stock has rebounded somewhat in recent months on the back of the shift in the FDA's position on rare diseases. Its share price remai...